DK1064303T3 - Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne - Google Patents

Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne

Info

Publication number
DK1064303T3
DK1064303T3 DK99913932T DK99913932T DK1064303T3 DK 1064303 T3 DK1064303 T3 DK 1064303T3 DK 99913932 T DK99913932 T DK 99913932T DK 99913932 T DK99913932 T DK 99913932T DK 1064303 T3 DK1064303 T3 DK 1064303T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
prostate
psma
extracellular domain
antibodies
Prior art date
Application number
DK99913932T
Other languages
Danish (da)
English (en)
Inventor
Gerald P Murphy
Alton L Boynton
Eric H Holmes
William Thomas Tino
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of DK1064303T3 publication Critical patent/DK1064303T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK99913932T 1998-03-18 1999-03-18 Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne DK1064303T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/044,668 US6150508A (en) 1996-03-25 1998-03-18 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
PCT/US1999/005864 WO1999047554A1 (en) 1998-03-18 1999-03-18 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen

Publications (1)

Publication Number Publication Date
DK1064303T3 true DK1064303T3 (da) 2007-09-17

Family

ID=21933651

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99913932T DK1064303T3 (da) 1998-03-18 1999-03-18 Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne

Country Status (13)

Country Link
US (1) US6150508A (ja)
EP (2) EP1064303B1 (ja)
JP (1) JP4229591B2 (ja)
AT (1) ATE361935T1 (ja)
AU (1) AU768558B2 (ja)
CA (1) CA2323096C (ja)
CY (1) CY1106790T1 (ja)
DE (1) DE69936049T2 (ja)
DK (1) DK1064303T3 (ja)
ES (1) ES2288017T3 (ja)
IL (2) IL138497A0 (ja)
PT (1) PT1064303E (ja)
WO (1) WO1999047554A1 (ja)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US7070782B1 (en) * 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
AU717937B2 (en) 1995-02-24 2000-04-06 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US7381407B1 (en) * 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) * 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO2001009192A1 (en) * 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
EP1710256A1 (en) * 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
US6379550B1 (en) * 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20020132983A1 (en) * 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP4463475B2 (ja) * 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2002305767B2 (en) * 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
EP1448588A4 (en) * 2001-10-23 2006-10-25 Psma Dev Company L L C ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
AU2002350623A1 (en) * 2001-10-26 2003-05-06 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
ATE534035T1 (de) 2002-05-08 2011-12-15 Northwest Biotherapeutics Inc Qualitätstests für antigenpräsentierende zellen
DK1537146T3 (da) 2002-07-15 2011-04-04 Univ Texas Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
EP1546714A4 (en) * 2002-08-30 2007-12-05 Univ Texas COMPOSITIONS AND METHODS FOR USE OF CON-US TARGETING PEPTIDES FOR THE DIAGNOSIS AND TREATMENT OF HUMAN CANCER
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
AU2003293556A1 (en) * 2003-01-10 2004-08-10 Millennium Pharmaceuticals, Inc. Methods of diagnosing and treating cancer
DK1587837T3 (da) * 2003-01-28 2012-09-24 Proscan Rx Pharma Inc Epitopsekvenser til diagnose og behandling af prostatacancer
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
CA2606138A1 (en) * 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
BRPI0607796A2 (pt) * 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
WO2006108763A1 (en) * 2005-04-08 2006-10-19 Nerviano Medical Sciences S.R.L. Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
US7718775B2 (en) * 2005-04-14 2010-05-18 Scinopharm Taiwan, Ltd. Monoclonal antibody with the capability of neutralizing enterovirus type 71 infection
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
BE1017200A3 (nl) * 2006-07-03 2008-04-01 Tekni Plex Europ Nv Filmstructuur met hoge zuurstofbarriere eigenschappen en werkwijze voor het vervaardigen van zulke filmstructuur.
WO2008150530A2 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
EP2197491A4 (en) 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
WO2009046294A2 (en) 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
KR101641345B1 (ko) 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
US7678581B2 (en) * 2008-01-28 2010-03-16 Clarient, Inc. Correlating chemical and spatial data within pathology samples
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
ES2438495T3 (es) 2008-09-08 2014-01-17 Psma Development Company, L.L.C. Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
EP3536700A1 (en) 2012-06-07 2019-09-11 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
LT2839860T (lt) 2012-10-12 2019-07-10 Medimmune Limited Pirolobenzodiazepinai ir jų konjugatai
BR112015023333A8 (pt) 2013-03-13 2018-04-17 Medimmune Ltd pirrolbenzodiazepinas e conjugados dos mesmos
US10022453B2 (en) 2013-12-23 2018-07-17 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
MX2017017172A (es) 2015-06-22 2018-02-23 Bayer Pharma AG Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN105542007A (zh) * 2016-02-03 2016-05-04 南昌大学 一种能特异结合前列腺特异性膜抗原胞外区的单域重链抗体
CN105524169A (zh) * 2016-02-03 2016-04-27 南昌大学 一种能特异结合前列腺特异性膜抗原的单域重链抗体
CN105524170A (zh) * 2016-02-03 2016-04-27 南昌大学 能特异结合前列腺特异性膜抗原的纳米抗体
RU2018136778A (ru) 2016-03-24 2020-04-24 Байер Фарма Акциенгезельшафт Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
BR112019012883A2 (pt) 2016-12-21 2019-11-26 Bayer Ag conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP7062901B2 (ja) * 2017-09-22 2022-05-09 東ソー株式会社 目的細胞の検出方法
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
SG11202012342WA (en) * 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP0668777B2 (en) * 1992-11-05 2011-02-09 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
WO1997035616A1 (en) * 1996-03-25 1997-10-02 Pacific Northwest Cancer Foundation Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains

Also Published As

Publication number Publication date
US6150508A (en) 2000-11-21
CY1106790T1 (el) 2012-05-23
EP1064303B1 (en) 2007-05-09
JP2002506629A (ja) 2002-03-05
EP1854808A2 (en) 2007-11-14
CA2323096C (en) 2004-10-19
JP4229591B2 (ja) 2009-02-25
PT1064303E (pt) 2007-08-21
CA2323096A1 (en) 1999-09-23
IL138497A0 (en) 2001-10-31
DE69936049T2 (de) 2008-01-10
ES2288017T3 (es) 2007-12-16
IL138497A (en) 2007-07-04
WO1999047554A1 (en) 1999-09-23
AU768558B2 (en) 2003-12-18
DE69936049D1 (de) 2007-06-21
ATE361935T1 (de) 2007-06-15
EP1854808A3 (en) 2008-02-27
EP1064303A4 (en) 2005-03-02
EP1064303A1 (en) 2001-01-03
AU3189699A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
PT973550E (pt) Anticorpos antagonistas anti-integrina avb3
ATE161582T1 (de) Monoklonale antikörper der maus
PT956506E (pt) Tratamento e diagnostico do cancro
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE160575T1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
ATE343597T1 (de) Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
TR199801027T2 (xx) Epitelyom te�his ve tedavisi i�in y�ntem.
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
DE59109139D1 (de) Immunologischer Nachweis von Metolachlor
ATE147788T1 (de) Immunologisches nachweisverfahren für triasulfuron